Market Chatter: Novartis Reports Two Confirmed Tumor Cases Linked to Neuromuscular Gene Therapy

MT Newswires Live11-06

Novartis (NVS) said testing has linked two tumor cases to its Zolgensma gene therapy, which treats spinal muscular atrophy, a rare genetic disease that causes progressive muscle weakness, Bloomberg reported Friday.

Since its approval in 2019, nine tumor cases have been reported in patients treated with Zolgensma, the report said. Novartis told Bloomberg it continues to monitor safety reports and assess all reported cases, though it has not confirmed the type or location of the tumors.

The drug's existing safety information warns of a potential tumor risk associated with the therapy's insertion into patients' DNA, Bloomberg reported.

Novartis did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment